《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2011年 > 4期

二氯醋酸二异丙胺改善糖尿病患者脂代谢紊乱的再评价

来自:中国糖尿病资讯网  编辑:lj|点击数:|2011-10-20

二氯醋酸二异丙胺改善糖尿病患者脂代谢紊乱的再评价

·糖尿病临床研究·

刘赫 韩萍 杜建玲 梁琳琅 董玉梅 武红梅 王晓露 窦艳华 施克新 刘国良

作者单位:110001沈阳,中国医科大学附属第一医院内分泌科(刘赫,刘国良);中国医科大学盛京医院(韩萍);大连医科大学第一医院(杜建玲);沈阳军区总医院(梁琳琅);辽宁省人民医院(董玉梅);辽宁医学院附属医院(武红梅);鞍山市中心医院(王晓露);锦州市中心医院(窦艳华);葫芦岛市中心医院(施克新)(第一作者现在北京协和医学院读博士)

通讯作者: 刘国良,E-mail: liuher1127@msn.com

【摘要】 目的 观察二氯醋酸二异丙胺(DIPA)对2型糖尿病(T2DM)患者脂代谢紊乱等的影响及安全性。 方法 对辽宁地区8个中心的TG≥4.0 mmol/L的T2DM患者240例进行随机阳性药物平行对照研究,DIPA组、非诺贝特组各120例。 结果 (1)两组治疗10 d、30 d后TG均显著下降(P<0.01);静脉滴注10 d后DIPA组TG下降4.53 mmol/L,非诺贝特组下降3.37 mmol/L,两组差异有统计学意义(P=0.036);继续口服20 d后两组分别下降5.45、4.33 mmol/L,两组差异无统计学意义(P=0.132)。(2)两组HDL-C在治疗前后及组间比较均无统计学差异(P>0.05)。(3)两组TC及LDL-C治疗后均下降(P<0.01),但组间差异无统计学意义(P>0.05)。(4)治疗30 d后DIPA组ALT明显下降(P<0.01),非诺贝特组无明显下降(P>0.05)。 结论 DIPA可明显改善糖尿病患者的TG、TC、LDL-C,疗效与非诺贝特相当,从ALT复常率的变化来看,DIPA不损害肝细胞功能。

doi:10.3969/j.issn.1006-6187.2011.04.015

A reevaluation of diisopropylamine dichloroacetate for its improvement of lipid metabolic disorder of diabetic patients

LIU He, HAN Ping,DU Jian-ling, et al. Department of Endocrinology, The 1st Affiliated Hospital of China Medical University, Shenyang 110001, China

Correspongding author: LIU Guo-liang, E-mail: liuhe1127@msn.com

【Abstract】 Objective To observe the therapeutic effects and safety of diisopropylamine dichloroacetate (DIPA) in improving lipid metabolic disorder of diabetic patients. Methods A randomized controlled trial with parallel positive drug was performed in 240 type 2 diabetic patients with TG≥4.0 mmol/L selected from 8 centers of Liaoning province. These patients were randomly divided into 2 groups: DIPA group (n=120) and fenofibrate group (n=120). Results (1)TG in both groups was significantly reduced after 10 or 30 days treatment (P<0.01). After the first 10 days treatment, the serum TG was reduced by 4.53 mmol/L in DIPA group, and 3.37 mmol/L in fenofibrate group (P=0.036). At the end of the 30 days treatment, the TG level was reduced by 5.45 mmol/L in DIPA group and by 4.33 mmol/L in fenofibrate groups. (2)There was no significant difference in HDL-C between two groups. (3)Both TC and LDL-C were significantly reduced (P<0.01), but there was no difference between two groups (P>0.05). (4)After 30 days treatment, ALT in DIPA group was recuced signicantly (P<0.01), but there was no difference in ALT level in fenofibrate group (P>0.05). Conclusions Like fenofibrate, DIPA is an effective and safe drug in treating lipid metabolic disorder of diabetic patients. But considering the normalization of ALT, DIPA may also protect the liver function.

【Key words】Diisopropylamine dichloroacetate; Fenofibrate; Diabetes mellitus, type 2;Triglyceride; Alanine aminotransferase

上一篇:两种胰岛素治疗方案对2型糖尿病合并骨折患者围手术期效果的回顾性比较研究 下一篇:人白血病相关蛋白16基因对3T3-L1脂肪细胞葡萄糖摄取及过氧化物酶体增殖物激活受体γ活性的影响